DTIL — PRECISION BIOSCIENCES INC

Nasdaq · Health Care · Biotechnology · CIK 1357874 ·
Last close
$7.58
Market Cap
$195.58M
52W High
$8.59
52W Low
$3.96
ADV30
222,860
Next earnings
2026-08-06
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 10,838,000 -9,075,000 -18,441,000 143,891,000 99,370,000 67,790,000
Dec 2025 34,204,000 12,508,000 20,133,000 154,416,000 110,823,000 62,168,000
Sep 2025 13,000 -20,667,000 -21,772,000 93,510,000 44,870,000 76,876,000
Jun 2025 18,000 -21,877,000 -23,520,000 108,928,000 62,242,000 74,874,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-65,843,000
Investing CF
$-634,000
Financing CF
$95,162,000
CapEx
$-797,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-5.13
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-528,188,000
Inventory
Receivables
$0
ST Investments
$4,762,000
EBIT TTM
$-45,187,000
Pretax Income TTM
$-46,609,000
Interest Exp TTM
$1,422,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$45,073,000
EBITDA
$-37,739,000
Free Cash Flow
$-21,668,250
Enterprise Value
$113,832,248
Total Cash
$101,184,000
Total Debt
$28,466,000
Shares Out
25,802,247
Trailing EPS
$-2.17
Book Value
$3.83
ROE
-70.9%
ROA
-18.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 34,264,000 -52,148,000 -45,724,000 154,416,000 62,168,000 -65,843,000
Dec 2024 68,696,000 -26,162,000 7,167,000 136,388,000 79,995,000 -58,445,000
Dec 2023 48,727,000 -43,736,000 -61,319,000 159,781,000 140,920,000 -84,114,000
Dec 2022 25,098,000 -62,308,000 -111,637,000 238,169,000 177,736,000 -45,753,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.92

Peers — same industry

TickerNameMarket CapLastDaily %
IPHYF Innate Pharma SA $211.28M $2.25
CRBU Caribou Biosciences, Inc. $214.23M $2.16
ABOS Acumen Pharmaceuticals, Inc. $174.79M $2.42
PLX Protalix BioTherapeutics, Inc. $172.42M $2.14
IKT Inhibikase Therapeutics, Inc. $224.46M $1.70

News headlines (Yahoo Finance, 1h cache)

[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate,
2026-05-21 17:30 · Yahoo
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
2026-05-21 11:01 · Yahoo
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
2026-05-14 11:01 · Yahoo
Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts
2026-05-13 11:07 · Yahoo
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
2026-05-05 12:25 · Yahoo
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-05 11:01 · Yahoo
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
2026-04-30 11:01 · Yahoo
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
2026-04-29 11:01 · Yahoo
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
2026-04-28 11:01 · Yahoo
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains?
2026-04-27 12:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.